Molecular Docking Study for Prediction of Chiral HPLC Separation of Hydroxychloroquine as an Alternative Antiviral of SARS-CoV-2
Author:
Moneteringtyas Prisca Caesa1, Kuncaka Agus1, Hermawan Dadan1, Mudasir Mudasir1ORCID
Affiliation:
1. Gadjah Mada University
Abstract
The HPLC chiral separation of hydroxychloroquine (HCQ) using chiral α-1-acid glycoprotein (AGP) column has been predicted based on a molecular docking approach. The research begins with the geometrical optimization of the HCQ compound using the quantum calculation method of semiempirical (SE) of PM6, AM1, and PM3, and Hartree-Fock (HF) and density functional theory (DFT/B3LYP) with the basis set of 3-21G, 6-31G, and 6-311G. Molecular docking was performed with AutoDock Vina and PyRx applications on exhaustiveness of 264. Redocking with AutoDock Vina was done using coordinates of X = 13.584; Y = 1.47; Z = 18.451 with a grid box size of 40 x 40 x 40 and a grid Spacing of 0.375 Å, followed by specific docking process using the same conditions as redocking. The DFT method with the basis set of 6-311G was the best calculation method because it gives the lowest PRESS and closest r2 value to one for the comparison between calculated and experimental data of 1H-NMR. The docking result shows that R-HCQ enantiomer has more negative value of binding energy and more diverse interactions in the inclusion complex, indicating that R-HCQ forms more stable complex with AGP, and therefore it will be retained longer in the AGP column and eluted from the column later after R-HCQ.
Publisher
Trans Tech Publications Ltd
Reference19 articles.
1. J. Grein, N. Ohmagari, D. Shin, G. Diaz, E. Asperges, A. Castagna, T. Feldt, G. Green, M.L. Green, F.-X. Lescure, E. Nicastri, R. Oda, K. Yo, E. Quiros-Roldan, A. Studemeister, J. Redinski, S. Ahmed, J. Bernett, D. Chelliah, D. Chen, S. Chihara, S.H. Cohen, J. Cunningham, Monforte, A. D'Arminio, S. Ismail, H. Kato, G. Lapadula, E. L'Her, T. Maeno, S. Majumder, Massari, M.M. Mora-Rillo, Y. Mutoh, D. Nguyen, E. Verweij, A. Zoufaly, A.O. Osinusi, A. DeZure, Y. Zhao, L. Zhong, A. Chokkalingam, E. Elboudwarej, L. Telep, L. Timbs, I. Henne, S. Sellers, H. Cao, S.K. Tan, L. Winterbourne, P. Desai, R. Mera, A. Gaggar, R.P. Myers, D.M. Brainard, R. Childs, T. Flanigan, Compassionate use of remdesivir for patients with severe Covid-19, N. Engl. J. Med. 10 (2020) 1–10. 2. A. Cortegiani, G. Ingoglia, M. Ippolito, A. Giarratano, S. Einav, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J. Crit. Care. 57 (2020) 279–283. 3. O. Mitjà, B. Clotet, Use of antiviral drugs to reduce COVID-19 transmission, Lancet Glob. Health. 8 (2020) 639–640. 4. J. Liu, R. Cao, M. Xu, X. Wang, H. Zhang, H. Hu, Y. Li, Z. Hu, W. Zhong, M. Wang, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov. 16 (2020) 6–9. 5. X. Yao, F. Ye, M. Zhang, C. Cui, B. Huang, P. Niu, X. Liu, L. Zhao, E. Dong, C. Song, S. Zhan, R. Lu, H. Li, W. Tan, D. Liu, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis. 71 (15) (2020) 732-739.
|
|